304 related articles for article (PubMed ID: 28624108)
41. Calcineurin inhibitors in liver transplantation: to be or not to be.
Castroagudín JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
42. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
43. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
[TBL] [Abstract][Full Text] [Related]
44. mTOR Inhibition and Clinical Transplantation: Liver.
Nashan B
Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
[TBL] [Abstract][Full Text] [Related]
45. Delayed Calcineurin Inhibitor Introduction Without Antibody Induction in Liver Transplantation Is Safe and Helps Preserve Kidney Function.
Tovikkai C; Limsrichamrern S; Dumronggittigule W; Sirivatanauksorn Y; Kositamongkol P; Mahawithitwong P; Sangserestid P; Assawasirisin C
Transplant Proc; 2021 Mar; 53(2):645-648. PubMed ID: 33358420
[TBL] [Abstract][Full Text] [Related]
46. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
47. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
48. Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study.
Alamo JM; Bernal C; Marín LM; Suárez G; Serrano J; Barrera L; Sousa JM; Padillo FJ; Gómez-Bravo MA
Transplant Proc; 2012 Sep; 44(7):2089-92. PubMed ID: 22974919
[TBL] [Abstract][Full Text] [Related]
49. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
50. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
[TBL] [Abstract][Full Text] [Related]
51. Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More.
Prashar R; Venkat KK
Adv Chronic Kidney Dis; 2016 Sep; 23(5):295-300. PubMed ID: 27742383
[TBL] [Abstract][Full Text] [Related]
52. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up.
Heeg MH; Mueller GA; Bramlage C; Homayounfar K; Muehlhausen J; Leha A; Koziolek MJ
Transplant Proc; 2013; 45(1):142-7. PubMed ID: 23375288
[TBL] [Abstract][Full Text] [Related]
53. Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation.
Pflugrad H; Schrader AK; Tryc AB; Ding X; Lanfermann H; Jäckel E; Schrem H; Beneke J; Barg-Hock H; Klempnauer J; Weissenborn K
Liver Transpl; 2018 Jan; 24(1):56-66. PubMed ID: 29156491
[TBL] [Abstract][Full Text] [Related]
54. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
[TBL] [Abstract][Full Text] [Related]
55. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
56. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
57. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
58. Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes.
Bittermann T; Lewis JD; Goldberg DS
Transplantation; 2022 Nov; 106(11):2182-2192. PubMed ID: 35706103
[TBL] [Abstract][Full Text] [Related]
59. CNI-sparing regimens within the liver transplant setting: experiences of a single center.
Beckebaum S; Cicinnati V; Brokalaki E; Frilling A; Gerken G; Broelsch CE
Clin Transpl; 2004; ():215-20. PubMed ID: 16704152
[TBL] [Abstract][Full Text] [Related]
60. Selection and use of immunosuppressive therapies after liver transplantation: current German practice.
Herzer K; Strassburg CP; Braun F; Engelmann C; Guba M; Lehner F; Nadalin S; Pascher A; Scherer MN; Schnitzbauer AA; Zimmermann T; Nashan B; Sterneck M
Clin Transplant; 2016 May; 30(5):487-501. PubMed ID: 26855333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
